...
首页> 外文期刊>Journal of Medicinal Chemistry >Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors
【24h】

Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors

机译:NSC12的合成,结构鉴定和生物学评估,NSC12是一种口服成纤维细胞生长因子(FGF)配体阱,用于治疗依赖于FGF的肺部肿瘤

获取原文
获取原文并翻译 | 示例

摘要

NSC12 is an orally available pan-FGF trap able to inhibit FGF2/FGFR interaction and endowed with promising antitumor activity. It was identified by virtual screening from a NCI small molecule library, but no data were available about its synthesis, stereochemistry, and physicochemical properties. We report here a synthetic route that allowed us to characterize and unambiguously identify the structure of the active compound by a combination of NMR spectroscopy and in silico conformational analysis. The synthetic protocol allowed us to sustain experiments aimed at assessing its therapeutic potential for the treatment of FGF-dependent lung cancers. A crucial step in the synthesis generated a couple of diastereoisomers, with only one able to act as a FGF trap molecule and to inhibit FGF-dependent receptor activation, cell proliferation, and tumor growth when tested in vitro and in vivo on murine and human lung cancer cells.
机译:NSC12是一种口服泛泛FGF捕获器,能够抑制FGF2 / FGFR相互作用,并具有有希望的抗肿瘤活性。它是通过NCI小分子文库中的虚拟筛选进行鉴定的,但尚无有关其合成,立体化学和理化性质的数据。我们在这里报告了一条合成路线,该路线使我们能够通过NMR光谱学和计算机构象分析相结合来表征和明确识别活性化合物的结构。合成方案使我们得以维持旨在评估其对FGF依赖性肺癌的治疗潜力的实验。合成中的关键步骤产生了两个非对映异构体,只有其中一个能够作为FGF陷阱分子并在鼠和人肺上进行体内和体外测试时能够抑制FGF依赖的受体活化,细胞增殖和肿瘤生长癌细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号